Stock LYRA LYRA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.3335 USD +2.46% Intraday chart for Lyra Therapeutics, Inc. -6.16% -93.64%
May. 21 Lyra Therapeutics Reduces Workforce to Extend Cash Runway MT
May. 21 Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
AQ
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
AQ
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics to Participate in Upcoming Investor Conferences
AQ
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
AQ
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
AQ
Lyra Therapeutics to Participate in Upcoming Investor Conferences
AQ
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
AQ
Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference
AQ
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lyra Therapeutics to Present at Jefferies Healthcare Conference
AQ
Lyra Therapeutics Announces $50.0 Million Private Placement
AQ
Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
AQ
Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference
AQ
Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LYRA Stock
  4. News Lyra Therapeutics, Inc.
  5. Press Releases